101. Synergistic or Additive Pharmacological Interactions between Magnoflorine and Cisplatin in Human Cancer Cells of Different Histological Origin
- Author
-
Jarogniew J. Luszczki, Marta Halasa, Anna Wawruszak, Daariimaa Khurelbat, Estera Okon, Wirginia Kukula-Koch, Andrzej Stepulak, and Agata Jarzab
- Subjects
magnoflorine ,Aporphines ,cisplatin ,isobolographic analysis ,Antineoplastic Agents ,Pharmacology ,Mass Spectrometry ,Article ,Catalysis ,Inorganic Chemistry ,lcsh:Chemistry ,chemistry.chemical_compound ,breast cancer ,Cell Line, Tumor ,medicine ,Humans ,Aporphine ,Physical and Theoretical Chemistry ,Lung cancer ,Rhabdomyosarcoma ,Menispermaceae ,Molecular Biology ,lcsh:QH301-705.5 ,Chromatography, High Pressure Liquid ,Spectroscopy ,Cell Proliferation ,Cisplatin ,biology ,Chemistry ,Alkaloid ,Organic Chemistry ,glioblastoma ,Drug Synergism ,General Medicine ,medicine.disease ,biology.organism_classification ,Chemotherapy regimen ,Computer Science Applications ,lung cancer ,lcsh:Biology (General) ,lcsh:QD1-999 ,Drug Resistance, Neoplasm ,rhabdomyosarcoma ,Magnoflorine ,medicine.drug - Abstract
Magnoflorine is an aporphine alkaloid present in plant species belonging to the Berberidaceae, Magnoliaceae, Menispermaceae, or Papaveraceae botanical families. The interest of magnoflorine has increased recently due to its multiplicity of pharmacological properties. The aim of this study was the analysis of combined anti-proliferative effect of magnoflorine and cisplatin and the assessment of drug&ndash, drug pharmacological interaction between these agents using isobolographic method in MDA-MB-468 human breast, NCIH1299 lung, TE671 rhabdomyosarcoma, or T98G glioblastoma cancer cell lines. Magnoflorine in combination with cisplatin at a fixed ratio of 1:1 augmented their anticancer action and yielded synergistic or additive pharmacological interactions by means of isobolographic method, therefore combined therapy using these two active agents can be a promising chemotherapy regimen in the treatment of some types of breast, lung, rhabdomyosarcoma, and glioblastoma cancers.
- Published
- 2020